acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor https://www.malacards.org/card/acute_myeloid_leukemia_and_myelodysplastic_syndromes_related_to_topoisomerase_type_2_inhibitor MEDGEN:1639654 icd11.foundation:88207494 AML and myelodysplastic syndromes related to topoisomerase type 2 inhibitor Orphanet:102381 GARD:0019836 UMLS:C4707659 MONDO:0015165 Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposid, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. therapy related acute myeloid leukemia and myelodysplastic syndrome